Issue
Title
Authors
Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer
Kolyadina I.V., Danzanova T.Y., Khokhlova S.V., Trofimova O.P., Kovaleva E.V., Rodionov V.V., Poddubnaya I.V.
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
Kolyadina I.V., Ganshina I.P., Kuzmicheva S.V., Tekeeva A.I., Kolokolov J.D., Volkonskii M.V., Poddubnaya I.V.
A population-based portrait of breast cancer in russia: a cancer register-based analysis in russian
Poddubnaya I.V., Kolyadina I.V., Kalashnikov N.D., Borisov D.A., Makarova M.V.
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
Kovalenko E.I., Artamonova E.V., Karabina E.V., Andreiashkina I.I., Prokof’eva E.A., Popova N.O., Gaisina E.A., Evstigneeva I.V., Shaidorov M.V., Zhiliaeva L.A., Ponomarenko D.M., Khasanova A.I., Mukhametshina G.Z., Koziakov A.E., Vorotilina L.V., Povyshev A.I., Simolina E.I., Marfutov V.V., Kozlov D.V., Suslova I.R., Shikina V.E., Karandeeva T.V., Shepel’ A.O., Kramskaia L.V., Oskirko D.A., Frolova O.S.
Avastin in clinical chemotherapy of malignant tumors
Gorbunova V.A.
Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii
Kolyadina I.V., Poddubnaya I.V., Trofimova O.P., Komov D.V., Karseladze A.I., Ermilova V.D., Vishnevskaya Y.V., Frank G.A., Banov S.M.
Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience)
Kolyadina I.V., Poddubnaya I.V., Van de Velde C.J., Kuppen P.J., Frank G.A., Komov D.V., Karseladze A.I., Bastiaannet E., Dekker-Ensink N.G.
Rare morphological forms of breast cancer: features of surgical approach
Vysotskaya I.V., Letyagin V.P., Kolyadina I.V., Martynova G.V.
The first results of the national programme for the diagnosis and treatment of HER2-positive breast cancer in Turkmenistan
Berdimyradova M.B., Khadjiev S.M., Khommadova D.N., Polatova G.O., Kakajanova A.O., Batyrov C.B., Penayev D.N., Agayeva B.G., Annaberdiyeva G.A.
Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype
Karabina E.V., Zhukova L.G.
Predictive factors of achievement pathological complete response at neoadjuvant chemotherapy of primary operable breast cancer
Pavlikova O.A., Kolyadina I.V., Komov D.V., Vishnevskaya Y.V., Poddubnaya I.V.
Prognostic value of p53 expression in patients with stage I breast cancer
Kolyadina I.V., Poddubnaya I.V., Van de Velde C.J., Kuppen P.J., Liefers G.J., Dekker-Ensink N.G., Bastiaannet E., Van As-Sajet A., Prinse B., Engels C., Van Vlierberghe R., Komov D.V., Karseladze A.I., Ermilova V.D., Vishnevskaya Y.V., Frank G.A., Banov S.M.
The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
Kolyadina I.V., Poddubnaya I.V.
The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer
Gordeeva O.O., Kolyadina I.V., Zhukova L.G., Gan'shina I.P., Komov D.V., Meshcheriakov A.A.
Denosumab (AMG-162) v profilaktike osteoporoza, vyzvannogo priemom ingibitorov aromatazy u bol'nykh rakom molochnoy zhelezy v ad\"yuvantnoy terapii i u bol'nykh rakom predstatel'noy zhelezy pri polnoy androgennoy blokade
Lichinitser M.R., Semenov N.N.
The use of combined plastic interventions in the reconstruction of post-operative soft tissue defects of the chest wall in the surgical treatment of locally advanced breast cancer
Vashenko L.N., Daschkova I.R., Bakulina S.M., Andreyko E.A.
PARP inhibitors in female reproductive system cancers
Pokataev I.A., Tyulyandin S.A.
Keliks (pegilirovannyy liposomal'nyy doksorubitsin) v programmnoy terapii 2-y linii metastaticheskogo raka molochnoy zhelezy
The potential use of oncolytic viruses in breast cancer: historical aspects and future prospects (literature review)
Morozov D.A., Kolyadina I.V., Poddubnaya I.V., Chumakov P.M., Ilinskaya G.V., Bokhian V.Y., Sopova M.I.
Effektivnost' ad\"yuvantnoy terapii anastrozolom i tamoksifenom u patsientok s rannimi stadiyami raka molochnoy zhelezy (analiz dannykh issledovaniya ATAC pri mediane vremeni nablyudeniya 100 mes)
Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
Kolbin A.S., Mosikyan A.A., Balykina Y.E., Proskurin M.A.
Rezul'taty «Epidemiologicheskoy programmy skrininga HER2-statusa u bol'nykh rakom molochnoy zhelezy» v Rossiyskoy Federatsii
Frank G.A., Poddubnaya I.V., Yagudina R.I., Borisov D.A.
The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience
Kolyadina I.V., Bulavina I.S., Petkau V.V., Strakhova N.V., Gorbunova V.A., Kovalenko E.I., Manziuk L.V., Artamonova E.V., Zhukova L.G., Bolotina L.V., Gan'shina I.P., Semiglazova T.I., Manikhas A.G., Raevskaia N.A., Itkin I.M., Khokhlova S.V., Filonenko D.V., Gol'dberg V.E., Popova N.O., Ponomarenko D.M., Shikina V.E., Vladimirova L.I., Tikhanovskaia N.M., Karabina E.V., Mukhametshina G.Z., Khasanova A.I., Safina S.Z., Shaidorov M.V., Orlov A.E., Kostalanova I.V., Levchenko N.V., Osipov M.A., Karandeeva T.V., Evstigneeva I.V., Chernov I.S., Kolokolov D.D., Povyshev A.I., Shatokhina A.S., Cherniakova E.M., Shkodenko O.N., Kuz'mina E.S.
The role and assessment of morphological regression after neoadjuvant therapy in breast cancer patients
Frank G.A., Ilatovskaia M.E., Andreeva I.I., Zavalishina L.E.
Modern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal women
Jackisch C., Llombart-Cussac A.
New chemotherapy options for triple-negative breast cancer (review of literature)
Sekundova M.A., Zdvizhkov A.M., Borisov V.I.
Circulating tumor cell: biology, methods of isolation, clinical significance in breast cancer
Nenahova Y.N., Lyadov V.K., Poddubnaya I.V.
Kachestvo zhizni i simptomyu bol'nykh disseminirovannym gormonopozitivnym rakom molochnoy zhelezy v postmenopauze na fone primeneniya Fazlodeksa
Novik A.A., Ionova T.I., Kalyadina S.A.
Femara (letrozol) v ad\"yuvantnoy terapii raka molochnoy zhelezy
Stenina M.B.
The results of Epidemiological HER2 screening program in patients with breast cancer in 2013
Frank G.A., Poddubnaya I.V., Yagudina R.I., Borisov D.A., Koroleva N.I.
Klinicheskaya effektivnost'i bezopasnost' primeneniya otechestvennogo rekombinantnogo granulotsitarnogo koloniestimuliruyushchego faktora Neypomaks® u bol'nykh rakom molochnoy zhelezy, poluchayushchikh khimioterapiyu doksorubitsinom i dotsetakselom
Zhukova L.G., Abramov M.E., Vakhabova Y.V., Lud A.N., Obukhov A.A., Lichinitser M.R.
Tayverb/Tyverb (lapatinib) – pervyy dvoynoy anti-ErbB1(EGFR)i anti-ErbB2(HER2)-ingibitor v lechenii mestno-rasprostranennogo i metastaticheskogo raka molochnoy zhelezy zaregistrirovan v Rossiyskoy Federatsii
Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population
Grechukhina K.S., Zhukova L.G.
HER-2-targetnaya terapiya raka molochnoy zhelezy: monoklonal'nye antitela i ingibitory tirozinkinazy
Ognerubova I.N.
Ad\"yuvantnaya endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy
Semiglazov V.F., Semiglazov V.V.
Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast
Rudakova A.V., Tolkacheva D.G., Gavrilova O.N., Vaganov A.S.
Difficulties in treating patients with breast cancer in Russia: the resolution on the results of the Review Board
Artamonova E.V., Gorbunova V.A., Zhukov N.V., Manzjuk L.V., Manihas A.G., Paltuev P.M., Semiglazov V.F., Semiglazova T.Y., Stenina M.B., Tjuljandin S.A., Chubenko V.A.
«Problema optimizatsii ad\"yuvantnoy endokrinnoy terapii na rannikh stadiyakh raka molochnoy zhelezy»
Semiglazov V.F., Poddubnaya I.V.
Klinicheskiy sluchay effektivnogo lecheniya lapatinibom (Tayverb)i kapetsitabinom (Kseloda) bol'noy disseminirovannym rakom molochnoy zhelezy s giperekspressiey ErbB2 (Her-2/neu) s metastaticheskim porazheniem veshchestva i obolochek golovnogo mozga
Naskhletashvili D.R., Chmutin G.E.
8 let nadezhdy: novye dannye issledovaniya ATAS
Dermatomyositis and polymyositis in breast cancer patients: a case reports
Ganshina I.P., Zhukova L.G., Burnevitch E.Z., Gordeeva O.O., Kondratieva O.E.
The results of Epidemiological HER2 screening program in patients with breast cancer in 2014
Poddubnaya I.V., Frank G.A., Yagudina R.I., Koroleva N.I., Zavalishina L.E.
Rol' Taksotera v lechenii metastaticheskogo raka molochnoy zhelezy
Kolyadina I.V., Makarenko N.P., Poddubnaya I.V.
Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving
Artamonova E.V.
The role of nab-paclitaxel in the treatment of patients with metastatic breast cancer
Frolova M.A.
Opyt primeneniya Regional'noy programmy v g. Krasnodare
Mitashok I.S.
Bone mineral density in patient with breast cancer
Poddubnaya I.V., Kizhaev E.V., Kolyadina I.V., Banov S.M., Zhmaeva E.M., Secko M.A.
Predoperatsionnaya (neoad\"yuvantnaya) endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy
Semiglazov V.F., Semiglazov V.V., Zhil'tsova E.K.
Sravnitel'noe issledovanie opredeleniya HER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii
Zavalishina L.E., Andreeva Y.Y., Ryazantseva A.A., Bateva M.V., Frank G.A.
Sovremennaya taktika ad\"yuvantnoy lekarstvennoy terapii bol'nykh operabel'nym (rannim) rakom molochnoy zhelezy
Perevodchikova N.I.
Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study
Ignatova E.O., Burdaeva O.N., Kopp M.V., Kotiv B.N., Udovitsa D.P., Stroiakovskii D.L., Alekseev S.M., Sheveleva L.P., Khorinko A.V., Shapovalova I.S., Moiseenko V.M., Ivanov R.A.
Radiation-induced lung injury in breast cancer patients after breast conservation therapy
Trofimova O.P., Tkachev S.I., Ivanov S.M., Utkina V.L., Cheban O.I., Glebovskaya V.V.
Press-release. «Sanofi» makes a contribution in improving availability of treatment in women with breast cancer in Russia in accordance with international standards
Current approach to adjuvant therapy for breast cancer (a review)
Conte P., Guarneri V.
Analiz rezul'tatov vnedreniya Regional'noy rossiyskoy programmy lecheniya pervichno-generalizovannogo i metastaticheskogo raka molochnoy zhelezy v Voronezhskom oblastnom klinicheskom onkologicheskom dispansere
Chevardov N.I., Tolstykh L.V., Puzakov K.G., Potapov Y.N.
Pharmacoeconomic characteristics of ixabepilone (Ixempra) monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
Kolbin A.S., Mosikyan A.A., Kurilev A.A., Balykina Y.E., Proskurin M.A.
Regional'naya programma lecheniya bol'nykh pervichno-generalizovannym i metastaticheskim rakom molochnoy zhelezy
Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials)
Kolyadina I.V., Poddubnaya I.V.
The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
Bolotina L.V., Manziuk L.V., Gorbunova V.A., Kovalenko E.I., Mukhametshina G.Z., Khasanova A.I., Vladimirova L.Y., Mitashok I.S., Prokofyeva E.P., Evstigneeva I.V., Andreyashkina I.I., Abramova N.A., Popova I.L., Karabina E.V., Teterich A.A., Gaysina E.A., Chubenko V.A., Limareva S.V., Tikhanovskaya N.M., Storozhakova A.E., Samaneva N.Y., Svetitskaya Y.V., Snezhko T.A., Kalabanova E.A.
Femara (letrozol) v sovremennoy terapii raka molochnoy zhelezy
Perevodchikova N.I.
Znachenie taksanov v neoad\"yuvantnoy terapii raka molochnoy zhelezy
Bozhok A.A., Semiglazov V.F., Kletsel' A.E., Arzumanov A.S., Ivanova O.A., Semiglazov V.V.
The post-mastectomy syndrome: the secondary lympedema after the combined treatment of breast cancer (the literature review and own results)
Stepanova A.M., Merzlyakova A.M., Khulamhanova M.M., Trofimova O.P.
Fulvestrant v sovremennoy terapii rasprostranennogo raka molochnoy zhelezy: farmakoekonomicheskoe obosnovanie
Komarova V.P., Komarova L.E., Poddubnaya I.V.
Dynamics of circulating tumor cells during neoadjuvant chemotherapy in patients with locally-advanced breast cancer
Nenakhova Y.N., Lyadov V.K., Poddubnaya I.V.
Neoadjuvant systemic therapy of HER2-positive breast cancer
Frolova M.A.
Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial
Ahmetzanov F.S., Ahmetzanova F.F.
Problemy endokrinoterapii raka molochnoy zhelezy u muzhchin
Borisova E.I., Voronina I.Y., Gutorov S.L.
The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation in 2015
Poddubnaya I.V., Frank G.A., Yagudina R.I., Koroleva N.I., Zavalishina L.E.
Opyt primeneniya Taksotera v kombinatsii s doksorubitsinom v kachestve khimioterapii 1-y linii u bol'nykh metastaticheskim rakom molochnoy zhelezy
Samoylenko V.M., Gorbunova V.A., Koshelev M.N., Yurashko K.V.
Faktory prognoza pri rake molochnoy zhelezy
Bozhok A.A., Semiglazov V.F., Semiglazov V.V., Arzumanov A.S., Kletsel' A.E.
Male breast cancer: review of the literature
Nikolaev K.S., Semiglazov V.F., Semiglazov V.V.
Postmastektomicheskaya limfedema verkhnikh konechnostey: vozmozhnosti konservativnogo lecheniya
Myasnikova M.O.
Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case
Kolyadina I.V., Ganshina I.P., Zhukova L.G., Abdullaev A.G., Andreeva Y.Y., Danzanova T.Y., Sinyukova G.T., Komov D.V., Kozlov N.A., Filonenko D.A., Gordeeva O.O., Lubennikova E.V.
Antiestrogennaya terapiya pri rake molochnoy zhelezy. Naskol'ko bezopasny ingibitory aromatazy?
Ptushkin V.V.
Farmorubitsin v klinicheskoy praktike
Gorbunova V.A.
Aromazin v ad\"yuvantnoy terapii raka molochnoy zhelezy
Artamonova E.V.
Ribociclib in 1st line HR+ breast cancer treatment
Zhukova L.G., Ganshina I.P., Gordeeva O.O., Lubennikova E.V.
Sravnitel'noe issledovanie opredeleniya NER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii
Zavalishina L.E., Andreeva Y.Y., Ryazantseva A.A., Bateva M.V., Frank G.A.
Sovremennye vozmozhnosti lekarstvennoy terapii operabel'nogo raka molochnoy zhelezy (po materialam St. Gallen, 2005)
Letyagin V.P., Vysotskaya I.V.
Opportunities of the pharmacogenetic approach to personalized tamoxifen breast cancer therapy: case reports
Savelyeva M.I., Dudina I.A., Zaharenkova J.S., Ignatova A.K., Ryzhikova K.A., Sozaeva Z.A., Kudlay D.A., Perfileva O.M., Poddubnaya I.V.
Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy
Krivorotko P.V., Burdaeva O.N., Nechaeva M.N., Frolova M.A., Kopp M.V., Abrosimova A.A., Ivanov R.A.
Bevatsizumab (Avastin) v kombinatsii s taksanami v 1-y linii lecheniya HER-2-negativnogo metastaticheskogo raka molochnoy zhelezy(Rezul'taty issledovaniya AVADO)
Zhukova L.G.
Immunogistokhimicheskoe opredelenie ekspressii HER2/neu pri rake molochnoy zhelezy (po dannym Smolenskogo oblastnogo onkologicheskogo klinicheskogo dispansera)
Shisterova O.A., Golik E.P.
Aromazin (ekzemestan) v neoad\"yuvantnoy i ad\"yuvantnoy gormonoterapii raka molochnoy zhelezy
Makarenko N.P.
Perspectives of pharmacogenetics approach to personalized tamoxifen therapy
Savelyeva M.I., Ignatova A.K., Panchenko Y.S., Urvantseva I.A., Poddubnaya I.V.
New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer
Semiglazova T.Y., Klyuge V.A., Semiglazov V.V., Teletaeva G.M., Krivorotko P.V., Dashyan G.A., Paltuev R.M., Tkachenko E.V., Donskikh R.V., Semiglazov V.F.
Press-reliz Na XIII Rossiyskom kongresse onkologov obsudili sostoyanie epidemiologicheskoy programmy skrininga HER2-statusa u zhenshchin, bol'nykh rakom molochnoy zhelezy (RMZh), a takzhe preimushchestvai perspektivy targetnoy terapii preparatami Gertseptin i Avastin
Case studies on clinical experience of targeted therapy ribociclib in combination with letrozole in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Frolova M.A., Kochetkova Y.I., Chubenko V.A., Volkov N.M., Moiseenko F.V., Garmarnik T.V., Ponomarenko D.M., Orlov A.E., Kostalanova Y.V., Makarycheva Y.Y., Nizegorodzeva A.A.
Albumin-bound paclitaxel in the treatment of metastatic breast cancer
Artamonova E.V.
Odnomomentnye mastektomii i laparoskopicheskie ovariektomii v lechenii raka molochnoy zhelezy
Khvastunov R.A., Kireev A.V., Nikol'skiy I.V., Suvorov V.A.
Stereotactic biopsy of breast lesions under x-ray control
Manikhas G.M., Safronova O.B., Khudjakova T.G., Barabanova L.P., Punanova N.J.
Personalized approach to HER2-positive advanced breast cancertherapy
Stenina M.B.
Vliyanie rekonstruktivno-plasticheskikh operatsiy na kachestvo zhizni bol'nykh rakom molochnoy zhelezy v otdalennom periode
Arslanov K.S., Tkachenko G.A.
Internal mammary nodes metastases for breast cancer: whether the morphological verification is necessary?
Trigolosov A.V., Uimanov V.A., Chernikh M.V., Petrovskiy A.V., Nikitina E.A., Nechushkin M.I.
Quality of life is the fundamental criterion of the efficacy of targeted therapy in patients with metastatic Her2-positive breast cancer
Semiglazova T.Y., Dashyan G.A., Semiglazov V.V., Zhabina A.S., Osipov M.A., Kotova Z.S., Klimenko V.V., Krivorotko P.V., Semiglazov V.F.
Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?
Zhukova L.G., Ganshina I.P., Khatkova E.I., Tikhomirova T.E., Kondratyeva O.E.
Tumor biology or adjuvant systemic therapy: what determines the risk of recurrence in breast cancer stage I?
Kolyadina I.V., Poddubnaya I.V., Trofimova O.P., Frank G.A., Karseladze A.I., Komov D.V.
The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature)
Semiglazov V.F., Semiglazov V.V., Paltuev P.M., Nikolaev K.S., Dashyan G.A.
Primenenie Zomety na fone endokrinnoy terapii Femaroy u bol'nykh rakom molochnoy zhelezy s metastazami v kosti
Konstantinova M.M., Ovchinnikova L.K., Lomakin N.N., Galleev M.G., Neretina E.S., Mukhamedshina G.Z., Mukhametgaleeva F.K.
Aromazin: printsip deystviya
Imyanitov E.N.
1 - 100 of 107 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies